SCHEMBL22320704

SCHEMBL22320704

Cc1c(Cl)c(O)c(Cl)c(C)c1-c1c(-c2ccc(F)cc2)oc2ncnc(Cl)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
KDM4E B2RXH2 2/20 0.41
HPGD P15428 2/20 0.41
UBE2N P61088 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TEK Q02763 6/20 0.36
KDR P35968 3/20 0.36
AURKA O14965 4/20 0.35
TNK2 Q07912 1/20 0.34
CHEK1 O14757 3/20 0.34
CDK1 P06493 1/20 0.34
MERTK Q12866 1/20 0.33
MAP2K1 Q02750 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22320626 0.86 TEK (0.42) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL22320612 0.84 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL6848486 0.78 TNK2 (0.58) ALDH1A1SMN1; SMN2KDM4EHPGDUBE2N
SCHEMBL22320657 0.77 TEK (0.47) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL20262700 0.77 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL1790077 0.77 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL6202986 0.77 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL6200319 0.73 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD
SCHEMBL6408208 0.73 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2KDM4EHPGDUBE2N
SCHEMBL20492595 0.73 SMN1; SMN2 (0.43) ALDH1A1SMN1; SMN2LMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255451-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE MCL1, BCL2A1, BCL2L10 ALDH1A1 647/4885SMN1; SMN2 609/4885LMNA 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.